AIMD

Company Overview — What Does Ainos, Inc. Do?

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California. Ainos, Inc. (AIMD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chun-Hsien Tsai and employs approximately 40 people. With a market capitalization of $10M, AIMD is one of the notable companies in the Healthcare sector.

Ainos, Inc. (AIMD) Stock Rating — Avoid (April 2026)

As of April 2026, Ainos, Inc. receives a Avoid rating with a composite score of 26.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.AIMD ranks #4,046 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ainos, Inc. ranks #707 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AIMD Stock Price and 52-Week Range

Ainos, Inc. (AIMD) currently trades at $1.68. The stock lost $0.01 (0.7%) in the most recent trading session. The 52-week high for AIMD is $4.50, which means the stock is currently trading -62.7% from its annual peak. The 52-week low is $0.44, putting the stock 279.9% above its annual trough. Recent trading volume was 10K shares, suggesting relatively thin trading activity.

Is AIMD Overvalued or Undervalued? — Valuation Analysis

Ainos, Inc. (AIMD) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.42x, versus the sector average of 2.75x. The price-to-sales ratio is 96.00x, compared to 1.66x for the average Healthcare stock.

At current multiples, Ainos, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ainos, Inc. Profitability — ROE, Margins, and Quality Score

Ainos, Inc. (AIMD) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -185.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -67.1% versus the sector average of -33.1%.

On a margin basis, Ainos, Inc. reports gross margins of 87.6%, compared to 71.5% for the sector. The operating margin is -82683.7% (sector: -66.1%). Net profit margin stands at -88057.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AIMD Debt, Balance Sheet, and Financial Health

Ainos, Inc. has a debt-to-equity ratio of 176.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.06x, suggesting adequate working capital coverage. Total debt on the balance sheet is $11M. Cash and equivalents stand at $1M.

AIMD has a beta of 1.64, meaning it is more volatile than the broader market — a $10,000 investment in AIMD would be expected to move 64.0% more than the S&P 500 on any given day. The stability factor score for Ainos, Inc. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ainos, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ainos, Inc. reported revenue of $112,013 and earnings per share (EPS) of $-3.46. Net income for the quarter was $-14M. Gross margin was 87.6%. Operating income came in at $-13M.

In FY 2025, Ainos, Inc. reported revenue of $124,157 and earnings per share (EPS) of $-3.46. Net income for the quarter was $-15M. Gross margin was 82.9%. Revenue grew 499.0% year-over-year compared to FY 2024. Operating income came in at $-14M.

In Q3 2025, Ainos, Inc. reported revenue of $1,690 and earnings per share (EPS) of $-0.64. Net income for the quarter was $-3M. Gross margin was 100.0%. Revenue grew 409.0% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Ainos, Inc. reported revenue of $4,663 and earnings per share (EPS) of $-0.99. Net income for the quarter was $-4M. Gross margin was 79.9%. Revenue grew 118.4% year-over-year compared to Q2 2024. Operating income came in at $-4M.

Over the past 8 quarters, Ainos, Inc. has demonstrated a growth trajectory, with revenue expanding from $-25,373 to $112,013. Investors analyzing AIMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AIMD Dividend Yield and Income Analysis

Ainos, Inc. (AIMD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AIMD Momentum and Technical Analysis Profile

Ainos, Inc. (AIMD) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.

AIMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ainos, Inc. (AIMD) ranks #707 out of 838 stocks based on the Blank Capital composite score. This places AIMD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AIMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AIMD vs S&P 500 (SPY) comparison to assess how Ainos, Inc. stacks up against the broader market across all factor dimensions.

AIMD Next Earnings Date

No upcoming earnings date has been announced for Ainos, Inc. (AIMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AIMD? — Investment Thesis Summary

The quantitative profile for Ainos, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. High volatility (stability score 14/100) increases portfolio risk.

In summary, Ainos, Inc. (AIMD) earns a Avoid rating with a composite score of 26.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AIMD stock.

Related Resources for AIMD Investors

Explore more research and tools: AIMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AIMD head-to-head with peers: AIMD vs AZN, AIMD vs SLGL, AIMD vs VMD.